The “Cytokine Storm” and Inflammatory Response to SARS-CoV-2
SARS-CoV-2 infection in patients has shown increased secretion of IL-1β, IFN-γ, IP-10/CXCL10, MCP-1/CCL2, IL-4, and IL-10. In addition, the infection has shown elevated levels of inflammatory cytokines such as IL-2, IL-6, IL-7, IL-10, G-CSF, IP-10/CXCL10, MCP-1/CCL2, MIP-1A, and TNF-α generating possible “cytokine storm”1,2. The treatment of cytokine storm has become increasingly important in helping coronavirus patients. Studies have shown that the IL-6R (Interleukin-6 Receptor) plays an important role in alleviating Cytokine Release Syndrome (CRS)2. While causes for inflammatory responses remain widely unknown, Leinco can assist researchers in providing many of these cytokines.
SARS-CoV-2 Increased Secretion & Inflammation of Cytokines
Cytokines
- -
- -
Product | Clone | Applications | Prod No. | Package Size |
|---|---|---|---|---|
I-218 | 100 µg ⋅ 20 µg ⋅ 500 µg | |||
I-453 | 10 µg ⋅ 100 µg ⋅ 1000 µg ⋅ 25 µg | |||
I-273 | 10 µg | |||
I-207 | 10 µg ⋅ 25 µg ⋅ 50 µg | |||
I-208 | 200 µg ⋅ 25 µg ⋅ 5 µg | |||
I-209 | 200 µg ⋅ 25 µg ⋅ 5 µg | |||
ELISA Cap | I-581 | 50 µg | ||
I-229 | 10 µg ⋅ 50 µg | |||
J100 | 10 µg ⋅ 50 µg | |||
M136 | 10 µg ⋅ 50 µg |
Antibodies to Cytokines
Additional conjugates available for each.
- -
- -
Product | Clone | Applications | Prod No. | Package Size |
|---|---|---|---|---|
MP1-22E9 | in vivo ⋅ N ⋅ WB | G741 | 1.0 mg ⋅ 100 mg ⋅ 25 mg ⋅ 5.0 mg ⋅ 50 mg | |
MP1-22E9 | FC ⋅ IHC FFPE ⋅ WB | G724 | 50 µg ⋅ 500 µg | |
HDß-4A7 | B ⋅ FA ⋅ in vivo ⋅ N ⋅ WB | I-1182 | 1.0 mg ⋅ 100 mg ⋅ 25 mg ⋅ 5.0 mg ⋅ 50 mg | |
MIB-5E9.1 | N ⋅ WB | I-440 | 50 µg ⋅ 500 µg | |
MIB-5E9.1 | in vivo ⋅ N ⋅ WB | I-439 | 1.0 mg ⋅ 100 mg ⋅ 25 mg ⋅ 5.0 mg ⋅ 50 mg | |
N ⋅ WB | I-232 | 100 µg ⋅ 25 µg | ||
XMG1.2 | CyTOF® ⋅ ELISA Cap ⋅ ELISPOT ⋅ ICFC ⋅ IHC FF ⋅ in vivo ⋅ N ⋅ WB | I-1119 | 1.0 mg ⋅ 100 mg ⋅ 25 mg ⋅ 5.0 mg ⋅ 50 mg | |
H22 | ELISA ⋅ IF ⋅ in vivo ⋅ IP ⋅ N ⋅ WB | I-438 | 1.0 mg ⋅ 100 mg ⋅ 25 mg ⋅ 5.0 mg ⋅ 50 mg | |
H22 | ELISA ⋅ IF ⋅ in vivo ⋅ IP ⋅ N ⋅ WB | I-1190 | 1.0 mg ⋅ 100 mg ⋅ 25 mg ⋅ 5.0 mg ⋅ 50 mg | |
JES5-2A5 | ELISA Cap ⋅ WB | C2157 | 50 µg ⋅ 500 µg |
ELISA Development Kits
- Y. Fu, et al. 2020, Virologica Sinica, 35:266–271
- C. Zhang, et al. 2020, International Journal of Antimicrobial Agents, 105954
- Image: G. Schett, et al. 2020, Nat Rev Immunol20, 271–272.
